54 related articles for article (PubMed ID: 38555985)
21. Overcoming endocrine resistance in hormone receptor-positive breast cancer.
AlFakeeh A; Brezden-Masley C
Curr Oncol; 2018 Jun; 25(Suppl 1):S18-S27. PubMed ID: 29910644
[TBL] [Abstract][Full Text] [Related]
22. Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer.
Nagaraj G; Ma C
Breast Cancer Res Treat; 2015 Apr; 150(2):231-42. PubMed ID: 25762475
[TBL] [Abstract][Full Text] [Related]
23. FGFs/FGFRs-dependent signalling in regulation of steroid hormone receptors - implications for therapy of luminal breast cancer.
Piasecka D; Braun M; Kitowska K; Mieczkowski K; Kordek R; Sadej R; Romanska H
J Exp Clin Cancer Res; 2019 May; 38(1):230. PubMed ID: 31142340
[TBL] [Abstract][Full Text] [Related]
24. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
McDaniel RE; Maximov PY; Jordan VC
Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
[TBL] [Abstract][Full Text] [Related]
25. Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment.
Teh JLF; Aplin AE
Clin Cancer Res; 2019 Feb; 25(3):921-927. PubMed ID: 30287548
[TBL] [Abstract][Full Text] [Related]
26. Mechanistic insight of drug resistance with special focus on iron in estrogen receptor positive breast cancer.
Mittal R; Chaudhry N; Pathania S; Mukherjee TK
Curr Pharm Biotechnol; 2014; 15(12):1141-57. PubMed ID: 25429654
[TBL] [Abstract][Full Text] [Related]
27. Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogen and Its Receptors in Cancer Physiopathology.
Segovia-Mendoza M; Morales-Montor J
Front Immunol; 2019; 10():348. PubMed ID: 30881360
[TBL] [Abstract][Full Text] [Related]
28. Membrane-initiated steroid signaling action of estrogen and breast cancer.
Song RX
Semin Reprod Med; 2007 May; 25(3):187-97. PubMed ID: 17447208
[TBL] [Abstract][Full Text] [Related]
29. Sex hormone receptors in breast cancer.
D'Abreo N; Hindenburg AA
Vitam Horm; 2013; 93():99-133. PubMed ID: 23810004
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of endocrine therapy resistance in breast cancer.
Rasha F; Sharma M; Pruitt K
Mol Cell Endocrinol; 2021 Jul; 532():111322. PubMed ID: 34000350
[TBL] [Abstract][Full Text] [Related]
31. Microenvironmental regulation of estrogen signals in breast cancer.
Yamaguchi Y
Breast Cancer; 2007; 14(2):175-81. PubMed ID: 17485903
[TBL] [Abstract][Full Text] [Related]
32. Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy.
Shao W; Brown M
Breast Cancer Res; 2004; 6(1):39-52. PubMed ID: 14680484
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptors: selective ligands, partners, and distinctive pharmacology.
Katzenellenbogen BS; Montano MM; Ediger TR; Sun J; Ekena K; Lazennec G; Martini PG; McInerney EM; Delage-Mourroux R; Weis K; Katzenellenbogen JA
Recent Prog Horm Res; 2000; 55():163-93; discussion 194-5. PubMed ID: 11036937
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic targeting in the estrogen receptor hormonal pathway.
Katzenellenbogen BS; Frasor J
Semin Oncol; 2004 Feb; 31(1 Suppl 3):28-38. PubMed ID: 15052541
[TBL] [Abstract][Full Text] [Related]
35. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
Veeraraghavan J; De Angelis C; Reis-Filho JS; Pascual T; Prat A; Rimawi MF; Osborne CK; Schiff R
Breast; 2017 Aug; 34 Suppl 1(Suppl 1):S19-S26. PubMed ID: 28687441
[TBL] [Abstract][Full Text] [Related]
36. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.
Cleator SJ; Ahamed E; Coombes RC; Palmieri C
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S6-S17. PubMed ID: 19561006
[TBL] [Abstract][Full Text] [Related]
37. Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and ER-Status: Stimulation of Estrogen Signaling Coupled With Breast Conserving Surgery.
Suba Z
Recent Pat Anticancer Drug Discov; 2016; 11(3):254-66. PubMed ID: 27087654
[TBL] [Abstract][Full Text] [Related]
38. Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic.
Fu X; De Angelis C; Schiff R
Endocrinology; 2022 Jan; 163(1):. PubMed ID: 34791151
[TBL] [Abstract][Full Text] [Related]
39. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies.
Saatci O; Huynh-Dam KT; Sahin O
J Mol Med (Berl); 2021 Dec; 99(12):1691-1710. PubMed ID: 34623477
[TBL] [Abstract][Full Text] [Related]
40. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Ciruelos Gil EM
Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
